Merck launches Sivextro in U.K.

Merck ($MRK) is launching Sivextro, the newly approved antibiotic it picked up in its $9.5 billion buyout of Cubist, in the U.K. Pharmafile reports it is the first oral treatment to be released in the oxazolidinone class of antibiotics in more than a decade. It is approved to treat acute bacterial skin and skin structure infections (ABSSSI), which are often caused by the MRSA superbug. Story

Suggested Articles

Which rollouts might suffer most? Those that treat chronic diseases, require doctors to administer them or face current competition, analysts say.

Novartis and Incyte will put their blockbuster JAK inhibitor into phase 3 clinical trials as a possible treatment for COVID-19, the drugmakers said.

The Cannes Lions canceled its advertising creativity conference for 2020 after media reports that many large ad agencies planned to opt out.